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ABSTRACT 
The successful integration of molecular imaging and radiation therapy has been shown to significantly impact the 
management of patients with non-small cell lung cancer (NSCLC). The collaboration of multidisciplinary team members, 
including radiation oncologists, radiation therapists, nuclear medicine physicians and physicists, has enabled PET/CT to 
be utilised for routine use throughout the radiotherapy treatment trajectory. Applications include disease diagnosis and 
staging, target volume definition for radiation therapy and monitoring tumour response to treatment. Not only has the 
adoption  of  this  technology  demonstrated  benefits  for  our  current  patients,  it  is  also  opening  doors  for  significant 
research in the future. © 2007 Biomedical Imaging and Intervention Journal. All rights reserved. 
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The safe and accurate delivery of radiation therapy 
(RT)  to  patients  with  cancer  has  always  demanded  a 
team  approach.  For  much  of  the  history  of  RT, 
treatments  could  be  planned  and  delivered  by  a  small 
team that included a physician and a radiation therapist 
together with the engineering and medical physics staff 
required  to  ensure  that  treatment  machines  gave  the 
output that was prescribed. In recent years, as treatments 
have become enormously more complex and somewhat 
more  effective,  the  membership  of  the  RT  team  has 
increased. The planning and delivery of RT frequently 
requires  contributions  from  radiation  oncologists, 
radiation therapists (also known as therapy radiographers 
in many countries), medical physicists and dosimetrists, 
together with nuclear medicine and diagnostic imaging 
specialists.  In  the  past,  many  of  these  specialist 
disciplines  have  tended  to  operate  in  autonomous 
environments. However, with the burgeoning complexity 
of  RT  planning  and  delivery,  these  disciplines  are 
increasingly integrating to combine their expertise for the 
benefit of patients treated with RT. 
One of the most striking recent examples of change 
is the increasingly close involvement of nuclear medicine 
in patient selection and RT treatment planning. Positron 
emission  tomography  (PET),  primarily  using  2-[
18F] 
fluoro-2-deoxy-D-glucose  (FDG)  as  the 
radiopharmaceutical, has increasingly been employed in 
the diagnosis and staging of non-small cell lung cancer 
(NSCLC) and other common cancers. In NSCLC, many 
studies  have  been  published  showing  that  PET  has  a 
significant  impact  on  the  selection  of  patients  for 
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curative therapy, most commonly surgery, by identifying 
candidates without gross systemic metastatic disease and 
without intrathoracic disease too extensive for an attempt 
at cure. PET scanning  was first employed at the Peter 
MacCallum Cancer Centre (Peter Mac) as a staging tool 
for patients with NSCLC a decade ago. At that time, we 
commenced  the  first  large  study  of  the  use  of  PET 
staging for NSCLC patients who were candidates not for 
surgery but for radical RT. In this prospective study PET 
staging  was  conducted  for  153  patients  considered 
eligible  for  radical  RT  based  on  the  results  of 
conventional staging investigations. Results of this study 
published by Mac Manus et al revealed that 46/153 (30%) 
patients were deemed ineligible for radical RT following 
PET because of detection of distant metastatic disease or 
intrathoracic disease too extensive for radical radiation 
[1].  Mah  et  al  reported  similar  findings,  stating  that 
where  PET  data  were  incorporated  into  the  disease 
staging process the treatment intent was changed from 
radical to palliative for 7 out of 30 patients (23%) [2]. 
Hicks  et  al  supported  the  work  of  other  researchers, 
reporting that in such cases where PET indicated a poor 
prognosis,  patients  were  spared  from  the  lengthy 
duration and unwarranted morbidity of futile aggressive 
treatment  [3].  In  addition  to  ensuring  that  only  those 
patients  who  are  most  likely  to  benefit  from  curative 
therapy were treated intensively, the significant costs and 
resources  associated  with  such  radical  treatment  were 
also avoided in these cases. These results have led to the 
routine incorporation of molecular imaging into the RT 
planning process at our centre. 
In  recent  years  there  have  been  many  attempts  to 
improve outcomes for patients with unresectable but still 
potentially  curable  NSCLC  through  altered  dose  and 
fractionation  regimens  and  by  prescribing  radiation  in 
combination  with  a  wide  range  of  chemotherapeutic 
agents. The most successful of these efforts have been 
the  use  of  continuous  hyper-fractionated  radiotherapy 
(CHART)  [4]  and  platinum  based  chemotherapy 
combined  with  RT  [5],  both  of  which  give  superior 
survival  to  conventional  RT  alone.  The  importance  of 
tumour imaging for RT target delineation and dosimetry 
is  becoming  increasingly  recognised  and  is  an  area  of 
intense  interest  at  present.  Even  the  most  effectively 
fractionated or highly chemo-sensitised RT will have a 
low chance for success if the tumour is not effectively 
contained within the high dose RT volume. Until the late 
1990’s,  target  volumes  for  RT  planning  were  based 
solely  on  diagnostic  CT  scan  data,  a  practice  that 
continues in  many centres today. Protocols for tumour 
delineation routinely documented that the gross tumour 
volume  (GTV)  included  the  primary  disease  and 
ipsilateral  hilar  and  mediastinal  lymph  nodes,  which 
were electively irradiated irrespective of their radiologic 
appearance. Since tumour volume delineation was based 
on  CT  alone,  all  lymph  nodes  thought  to  be  involved 
(>1cm short axis diameter) were also encompassed in the 
volume. In centres where elective nodal irradiation is not 
routine, a 1.5–2.0cm margin is typically applied to the 
GTV, and an additional margin is often applied to allow 
for motion of the tumour with the respiratory cycle, the 
sum  of  these,  thereby  generating  the  planning  target 
volume  (PTV).  The  PTV  is  the  volume  that  must  be 
treated  as  uniformly  as  possible  to  the  prescribed 
radiation  dose  and  critical  tissues  outside  this  volume 
should be treated to as low a dose of radiation as possible. 
With  the  advent  of  PET  imaging,  the  process  of 
defining RT target volumes is changing. Many studies 
have reported the potential advantages of PET-assisted 
target  volume  definition  in  NSCLC  [1,2,6-15].  These 
studies suggest that the benefits of PET in staging this 
disease, particularly through more reliable identification 
of  tumour  bearing  lymph  nodes,  also  translate  into 
superior target definition. The superior accuracy of PET 
over  CT  in  staging  mediastinal  lymph  nodes  has  been 
demonstrated by a large number of prospective studies 
[16-21]. In a comprehensive meta-analysis Toloza et al 
reviewed 18 studies that used PET and 20 that used CT 
for staging mediastinal disease [16]. They demonstrated 
that the accuracy of CT scanning for mediastinal staging 
had  not  improved  over  the  past  decade,  despite 
improvements in CT scan resolution [16]. Of the 3438 
patients examined, the pooled sensitivity of CT scanning 
was  0.57  (95%  CI,  0.49  to  0.66),  and  the  pooled 
specificity  was  0.82  (95%  CI,  0.77  to  0.86).  Another 
meta-analysis of 42 CT studies performed between 1980 
and 1988 reported sensitivities of 79% and specificities 
of 78% [22]. The superiority of PET is highlighted in the 
meta-analysis  by  Toloza  et  al,  where  sensitivity  and 
specificity for mediastinal staging were reported as 84% 
(95% CI, 0.78 to 0.89), and 89% (95% CI, 0.83 to 0.93), 
respectively. Other authors not included in the analysis 
by Toloza et al have also reported similar results [17,18, 
23]. Overall, these authors have demonstrated increased 
evidence and confidence in the ability of PET to detect 
tumour in normal sized lymph nodes and also to exclude 
tumour  in  abnormally  enlarged  nodes.  As  a  result  of 
these  findings,  the  radiotherapeutic  management  of 
patients with mediastinal involvement can reasonably be 
altered by taking PET information into account [18].  
Another  significant  advantage  of  PET  in  target 
volume delineation is its ability to differentiate tumour 
from  atelectatic  lung  with  greater  accuracy  than  other 
imaging  modalities  [6,7,9,12].  This  is  particularly 
difficult  to  achieve  using  the  morphologic  information 
given  by  CT  [11].  Without  PET  information,  target 
volumes may incorporate unnecessarily large volumes of 
disease free collapsed or consolidated lung. Conversely, 
3DCRT  target  volumes  based  on  PET/CT  information 
focus radiation on metabolically active disease, thereby 
sparing  adjacent  normal  lung  tissue  from  unnecessary 
dose and reducing the potential for radiation pneumonitis. 
At  our  institution  we  began  to  incorporate  PET 
information into the process of tumour volume definition 
for patients planned to receive RT for NSCLC in 1996. 
Radiation oncologists incorporated PET data into the RT 
treatment planning process simply by visually estimating 
the location and extent of PET positive structures on PET 
hard  copies  in  relation  to  anatomical  landmarks  on 
planning  CT  scans.  The  impact  of  this  method  was SJ Everitt et al. Biomed Imaging Interv J 2007; 3(1):e3    3 
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assessed  for  102  eligible  patients  at  our  centre  [1]. 
Overall, 41/102 (40%) patients required changes to their 
RT  plan  to  ensure  appropriate  treatment  of  tumour 
detected by PET. In 22/102 (22%) cases PET led to a 
significant  increase  in  the  target  volume  because  of 
inclusion  of  structures  previously  considered  not 
involved  by  tumour.  In  16/102  (16%)  cases  the  target 
volume  was  significantly  reduced,  where  PET 
demonstrated  areas  of  lung  collapse  or  consolidation 
and/or enlarged lymph nodes with low 18F-FDG uptake 
that  were  excluded  from  the  treatment  volume.  In 
addition to this, primary tumours seen on PET were not 
identified on CT in 3/102 (3%) patients. 
This was an ad-hoc, low technology method that did 
not fully utilise the three-dimensional information from 
PET. At the time we had no means of incorporating PET 
information directly into the treatment planning software. 
As previously published, one of our physicists overcame 
this barrier by writing software that allowed importation 
and co-registration of separately acquired PET and CT 
images  [24].  This  technique  was  investigated  for  10 
consecutive  patients  with  NSCLC.  The  method  was 
robust  and  practical  and  we  saw  similar  changes  in 
PET/CT plans compared to CT-alone plans to those that 
were observed in our earlier studies performed without 
co-registration.  
Other studies have demonstrated similar findings to 
our  own  [2,6,8,9,12-14].  Bradley  et  al  reported  that 
14/24  patients  (58%)  planned  for  definitive  RT  had 
significant alterations in the GTV and PTV, attributable 
to the detection by PET of additional nodal (n=10) or 
primary  disease  (n=1)  or  to  the  demarcation  of  gross 
tumour  within  atelectatic  lung  (n=3)  [6].  Erdi  et  al 
reported  that  the  PTV  was  increased  in  7/11  (64%) 
patients studied, to incorporate additional regional nodal 
disease detected with PET [8]. In a retrospective study, 
Nestle  et  al  reported  that  the  incorporation  of  overall 
PET findings altered the shape of the radiation portals in 
12/34  (35%)  patients  [12].  Similarly,  Kiffer  et  al 
reported the use of PET images for planning would have 
altered the RT portals in 7/15 patients (47%) [13]. In all 
studies, the inclusion of PET has had a significant impact 
on target volume definition in a substantial proportion of 
patients  (approximately  30–60%),  and  in  those  cases 
PET  has  influenced  the  design  of  the  PTV  and 
consequently  the  design  of  RT  dosimetry  to  ensure 
optimal coverage of the tumour. Each of these changes 
could be expected to lead to more accurate delineation of 
target  volumes  for  3DCRT.  In  turn,  improvements  in 
tumour coverage may have facilitated improved patient 
outcomes  through  minimised  risks  of  excluding  gross 
tumour  and  avoidance  of  unnecessarily  irradiating 
surrounding  normal  tissues,  although  this  would  be 
exceedingly difficult to prove. 
In 2001, the Centre for Molecular Imaging at Peter 
Mac acquired an integrated PET-CT scanner, providing 
true  fused  images  for  RT  planning.  Our  previous  co-
registration method became obsolete at a stroke. Because 
PET  and  CT  data  are  acquired  at  a  single  session 
potential  inaccuracies  associated  with  separate 
acquisitions were eliminated, including patient position 
reproducibility,  different  breathing  patterns  and  errors 
associated with fiducial marker co-registration and image 
registration. Both CT and PET data are readily visualised 
simultaneously on the RT planning computer for target 
volume delineation. This system is now routinely used 
for all patients treated with radical RT for NSCLC and 
oesophageal  cancer  at  our  centre.  PET  information  is 
also commonly used to assist with RT target definition in 
cervix and head and neck cancers, paediatric cancers and 
lymphomas.  
Successfully integrating this technology into routine 
practice  has  relied  upon  continuous  and  effective 
communication  between  disciplines  in  molecular 
imaging  and  RT,  including  physicians,  radiation 
therapists,  nuclear  medicine  technologists  and  medical 
physicists. The nuclear medicine physician plays a key 
role  in  assisting  the  radiation  oncologist  to  accurately 
contour  gross  tumour.  Radiation  oncologists  generally 
have  little  training  in  PET  and  without  expert  support 
may not use PET information effectively. As a team we 
acknowledged the potential pitfalls and sources of error 
involved in this process and invested considerable effort 
to  ensure  reproducibility  of  scanning  conditions  and 
consistency of PET/CT image display on RT planning 
computers.  Because  radiation  oncologists  undertake 
target volume delineation in close consultation with their 
diagnostic imaging colleagues, a true multi-disciplinary 
assessment occurs. We therefore believe that the highest 
quality  information  available  to  us  is  used  for  target 
volume determination. 
A key goal of research in radiation oncology is to 
maximise the therapeutic ratio. The addition of PET to 
CT for defining target volumes for RT has the potential 
to  help  achieve  this  goal  by  targeting  the  tumour 
accurately  and  sparing  normal  structures  previously 
thought to contain tumour. We are currently conducting a 
prospective study that will recruit 50 patients who go on 
to receive radical RT for NSCLC after PET staging. A 
similar  study  is  commencing  in  the  USA  under  the 
auspices  of  the  Radiation  Therapy  Oncology  Group 
(RTOG). Each of these studies will compare dosimetry 
based  on  tumours  defined  with  PET/CT  compared  to 
volumes derived using CT alone. In time, we hope that 
valuable information relating to tumour control, normal 
tissue  toxicity  and  patient  survival  will  validate  the 
impact of PET on overall patient outcomes.  
Apart  from  initial  target  volume  definition,  there 
remains great potential to further improve outcomes for 
patients with NSCLC. Preliminary research has explored 
the value of integrating PET data into during-treatment 
and  post-treatment  tumour  assessment.  A  recent  Peter 
Mac study by MacManus et al investigated patterns of 
metabolic tumour response and disease progression for 
88 patients after PET information was used together with 
CT  to  stage  and  plan  radical  RT  [3].  73/88  (83%) 
patients  received  concurrent  platinum-based  radical 
chemo/RT and 15/88 (17%) received radical RT alone. A 
restaging PET scan, performed to investigate patterns of 
metabolic tumour response, was conducted at a median SJ Everitt et al. Biomed Imaging Interv J 2007; 3(1):e3    4 
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time  of  70  days  after  treatment.  The  scan  results 
demonstrated that the tumour was stable in 72/88 (81%) 
patients,  including  40/88  (45%)  who  had  attained  a 
complete  metabolic  response.  However,  by  the  final 
follow-up  at  four  years  70/88  (80%)  patients 
demonstrated progressive disease with disease relapsing 
locally in 62/88 (71%), either alone or in combination 
with  distant  metastasis.  Only  17/88  (19%)  patients 
survived for four years. Of all the patients who attained a 
complete  metabolic  response  half  eventually  had  local 
failure.  The  very  high  rate  of  local  progression  after 
radical RT confirms yet again that a prescribed radiation 
dose  60Gy  is  inadequate  to  control  more  than  a  low 
percentage of lung cancers, even  when combined  with 
concurrent chemotherapy. Nevertheless, the high rate of 
isolated  loco-regional  recurrence  suggests  that 
intensification of local therapy could potentially improve 
outcomes in future clinical trials.  
In  conclusion,  we  believe  that  the  combination  of 
advanced  imaging  with  advanced  RT  planning  is  an 
excellent  example  of  how  teamwork  and  a  true 
multidisciplinary  approach  can  help  us  harness  new 
technology  for  the  future  benefit  of  our  patients.  New 
avenues for research are opening up that suggest that the 
future potential of this approach is immense. 
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